Form 4 for TENX TENAX THERAPEUTICS, INC.
Accepted 2026-05-13 17:08:07 ET · period of report 2026-05-11 · accession 0001193125-26-221926 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-13 17:08 | 2026-05-11 | TENX | STAAB THOMAS R II | CFO | A - Grant | $0.00 | +10.0K | 10.0K | New | $0 |
| D | 2026-05-13 17:08 | 2026-05-11 | TENX | STAAB THOMAS R II | CFO | A - Grant | $0.00 | +450.0K | 450.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-11 | A | A | 10,000 | $0.00 | 10,000 | D | — | — | (F1) Represents a restricted stock award which vests 25% ten days after the grant date, with the remainder vesting in three equal installments on the four-month, eight-month and twelve-month anniversaries of the grant date, subject to the Reporting Person's continued employment. |
| 2 | Derivative | Stock Option (right to buy) | 2026-05-11 | A | A | 450,000 | $0.00 | 450,000 | D | $11.95 · — to 2036-05-11 | 450,000 Common Stock | (F2) The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment. |